These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2140 related articles for article (PubMed ID: 18320593)

  • 21. 5alpha-Androstane-3beta,17beta-diol (3beta-diol), an estrogenic metabolite of 5alpha-dihydrotestosterone, is a potent modulator of estrogen receptor ERbeta expression in the ventral prostrate of adult rats.
    Oliveira AG; Coelho PH; Guedes FD; Mahecha GA; Hess RA; Oliveira CA
    Steroids; 2007 Dec; 72(14):914-22. PubMed ID: 17854852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of the major oxidative 3alpha-hydroxysteroid dehydrogenase in human prostate that converts 5alpha-androstane-3alpha,17beta-diol to 5alpha-dihydrotestosterone: a potential therapeutic target for androgen-dependent disease.
    Bauman DR; Steckelbroeck S; Williams MV; Peehl DM; Penning TM
    Mol Endocrinol; 2006 Feb; 20(2):444-58. PubMed ID: 16179381
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PI3K-Akt signaling is involved in the regulation of p21(WAF/CIP) expression and androgen-independent growth in prostate cancer cells.
    Lu S; Ren C; Liu Y; Epner DE
    Int J Oncol; 2006 Jan; 28(1):245-51. PubMed ID: 16328002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulation of androgen receptor levels: implications for prostate cancer progression and therapy.
    Burnstein KL
    J Cell Biochem; 2005 Jul; 95(4):657-69. PubMed ID: 15861399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of SULT2B1b expression alters effects of 3beta-hydroxysteroids on cell proliferation and steroid hormone receptor expression in human LNCaP prostate cancer cells.
    He D; Falany CN
    Prostate; 2007 Sep; 67(12):1318-29. PubMed ID: 17626250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells.
    Rizner TL; Lin HK; Peehl DM; Steckelbroeck S; Bauman DR; Penning TM
    Endocrinology; 2003 Jul; 144(7):2922-32. PubMed ID: 12810547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgen receptor and TGFbeta1/Smad signaling are mutually inhibitory in prostate cancer.
    van der Poel HG
    Eur Urol; 2005 Dec; 48(6):1051-8. PubMed ID: 16257107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Formation of 5α-dihydrotestosterone from 5α-androstane-3α,17β-diol in prostate cancer LAPC-4 cells - Identifying inhibitors of non-classical pathways producing the most potent androgen.
    Boutin S; Roy J; Maltais R; Poirier D
    Bioorg Med Chem Lett; 2020 Jan; 30(2):126783. PubMed ID: 31753699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dihydrotestosterone interacts with EGFR/MAPK signalling and modulates EGFR levels in androgen receptor-positive LNCaP prostate cancer cells.
    Mukherjee B; Mayer D
    Int J Oncol; 2008 Sep; 33(3):623-9. PubMed ID: 18695894
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
    Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
    Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
    Zhang M; Latham DE; Delaney MA; Chakravarti A
    Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
    Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
    Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prolactin influences upon androgen action in male accessory sex organs.
    Thomas JA; Keenan EJ
    Adv Sex Horm Res; 1976; 2():425-70. PubMed ID: 189591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impaired dihydrotestosterone catabolism in human prostate cancer: critical role of AKR1C2 as a pre-receptor regulator of androgen receptor signaling.
    Ji Q; Chang L; Stanczyk FZ; Ookhtens M; Sherrod A; Stolz A
    Cancer Res; 2007 Feb; 67(3):1361-9. PubMed ID: 17283174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemical synthesis and biological activities of 16alpha-derivatives of 5alpha-androstane-3alpha,17beta-diol as antiandrogens.
    Roy J; Breton R; Martel C; Labrie F; Poirier D
    Bioorg Med Chem; 2007 Apr; 15(8):3003-18. PubMed ID: 17336533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgen-induced Wnt signaling in preosteoblasts promotes the growth of MDA-PCa-2b human prostate cancer cells.
    Liu XH; Kirschenbaum A; Yao S; Liu G; Aaronson SA; Levine AC
    Cancer Res; 2007 Jun; 67(12):5747-53. PubMed ID: 17575141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Zanthoxyli Fructus induces growth arrest and apoptosis of LNCaP human prostate cancer cells in vitro and in vivo in association with blockade of the AKT and AR signal pathways.
    Yang Y; Ikezoe T; Takeuchi T; Adachi Y; Ohtsuki Y; Koeffler HP; Taguchi H
    Oncol Rep; 2006 Jun; 15(6):1581-90. PubMed ID: 16685399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer.
    Horvath LG; Lelliott JE; Kench JG; Lee CS; Williams ED; Saunders DN; Grygiel JJ; Sutherland RL; Henshall SM
    Prostate; 2007 Jul; 67(10):1081-90. PubMed ID: 17476687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of prostate cancer cell survival after inhibition of AR expression.
    Cohen MB; Rokhlin OW
    J Cell Biochem; 2009 Feb; 106(3):363-71. PubMed ID: 19115258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate androgen-regulated gene: a novel potential target for androgen-independent prostate cancer therapy.
    Xu XF; Zhou SW; Zhang X; Ye ZQ; Zhang JH; Ma X; Zheng T; Li HZ
    Asian J Androl; 2006 Jul; 8(4):455-62. PubMed ID: 16763722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 107.